Exogenous Kallikrein Protects Against Diabetic Nephropathy.
Wenjuan Liu,Yeping Yang,Yemei Liu,Xiaolan Lu,Shizhe Guo,Meng Wu,Meng Wang,Linling Yan,Qinghua Wang,Xiaolong Zhao,Xian Tong,Ji Hu,Yiming Li,Renming Hu,Robert C. Stanton,Zhaoyun Zhang
DOI: https://doi.org/10.1016/j.kint.2016.06.018
IF: 19.6
2016-01-01
Kidney International
Abstract:The kallikrein-kinin system has been shown to be involved in the development of diabetic nephropathy, but specific mechanisms are not fully understood. Here, we determined the renal-protective role of exogenous pancreatic kallikrein in diabetic mice and studied potential mechanisms in db/db type 2 diabetic and streptozotocin-induced type 1 diabetic mice. After the onset of diabetes, mice were treated with either pancreatic kallikrein (db/db + kallikrein, streptozotocin + kallikrein) or saline (db/db + saline, streptozotocin + saline) for 16 weeks, while another group of streptozotocin-induced diabetic mice received the same treatment after onset of albuminuria (streptozotocin' + kallikrein, streptozotocin' + saline). Db/m littermates or wild type mice were used as non-diabetic controls. Pancreatic kallikrein had no effects on body weight, blood glucose and blood pressure, but significantly reduced albuminuria among all three groups. Pathological analysis showed that exogenous kallikrein decreased, the thickness of the glomerular basement membrane, protected against the effacement of foot process, the loss of endothelial fenestrae, and prevented the loss of podocytes in diabetic mice. Renal fibrosis, inflammation and oxidative stress were reduced in kallikrein-treated mice compared to diabetic controls. The expression of kininogen1, tissue kallikrein, kinin B1 and B2 receptors were all increased in the kallikrein-treated compared to saline-treated mice. Thus, exogenous pancreatic kallikrein both prevented and ameliorated diabetic nephropathy, which may be mediated by activating the kallikrein-kinin system.